» Articles » PMID: 24530149

Screening and Identification of T Helper 1 and Linear Immunodominant Antibody-binding Epitopes in Spike 1 Domain and Membrane Protein of Feline Infectious Peritonitis Virus

Overview
Journal Vaccine
Date 2014 Feb 18
PMID 24530149
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Feline infectious peritonitis virus (FIP virus: FIPV) causes a fatal disease in wild and domestic cats. The development of an FIP-preventive vaccine requires an antigen that does not induce antibody-dependent enhancement, and T helper (Th)1 activity plays an important role in protect against FIPV infection. In the present study, we identified synthetic peptides including Th1 and a linear immunodominant antibody-binding epitope in the S1 domain and M protein of FIPV. We also identified peptides that strongly induce Th1 activity from those derived from the structural proteins (S, M, and N proteins) of FIPV based on this and previous studies (Satoh et al. [19]). No Th1 epitope-containing peptide was identified in the peptides derived from the S1 domain of type I FIPV. In contrast, 7 Th1 epitope-containing peptides were identified in the S1 domain of type II FIPV, and no linear immunodominant antibody-binding epitope was contained in any of these peptides. Eleven Th1 epitope-containing peptides common to each serotype were identified in the M protein-derived peptides, and 2 peptides (M-11 and M-12) contained the linear immunodominant antibody-binding epitope. Of the peptides derived from the S, M, and N proteins of FIPV, those that induced significantly stronger Th1 activity than that of the FIPV antigen were rescreened, and 4 peptides were identified. When 3 of these peptides (M-9, I-S2-15, and II-S1-24) were selected and administered with CpG-ODNs to SPF cats, M-9 and II-S1-24 induced Th1 activity. Our results may provide important information for the development of a peptide-based vaccine against FIPV infection.

Citing Articles

Development and Application of an Indirect Enzyme-Linked Immunosorbent Assay Based on a Recombinant Matrix Protein for the Serological Study of Porcine Deltacoronavirus in Mexican Pigs.

Castaneda Montes F, Cerriteno Sanchez J, Cuevas-Romero J, Castaneda Montes M, Mendoza Elvira S Vet Med Sci. 2024; 10(6):e70108.

PMID: 39494986 PMC: 11533212. DOI: 10.1002/vms3.70108.


Immunoinformatics-aided rational design of a multi-epitope vaccine targeting feline infectious peritonitis virus.

Chawla M, Cuspoca A, Akthar N, Magdaleno J, Rattanabunyong S, Suwattanasophon C Front Vet Sci. 2024; 10:1280273.

PMID: 38192725 PMC: 10773687. DOI: 10.3389/fvets.2023.1280273.


A Candidate Antigen of the Recombinant Membrane Protein Derived from the Porcine Deltacoronavirus Synthetic Gene to Detect Seropositive Pigs.

Castaneda-Montes F, Cerriteno-Sanchez J, Castaneda-Montes M, Cuevas-Romero J, Mendoza-Elvira S Viruses. 2023; 15(5).

PMID: 37243136 PMC: 10222885. DOI: 10.3390/v15051049.


Antigen epitopes of animal coronaviruses: a mini-review.

Su M, Zheng G, Xu X, Song H Anim Dis. 2023; 3(1):14.

PMID: 37220551 PMC: 10189233. DOI: 10.1186/s44149-023-00080-0.


Immunodominant B-Cell Linear Epitope on the VP1 P Domain of a Feline Norovirus Cat Model.

Takano T, Ryu M, Doki T, Kusuhara H Pathogens. 2022; 11(7).

PMID: 35889977 PMC: 9316177. DOI: 10.3390/pathogens11070731.


References
1.
Pedersen N, Black J . Attempted immunization of cats against feline infectious peritonitis, using avirulent live virus or sublethal amounts of virulent virus. Am J Vet Res. 1983; 44(2):229-34. View

2.
Weiss R, Scott F . Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis. 1981; 4(2):175-89. PMC: 7134169. DOI: 10.1016/0147-9571(81)90003-5. View

3.
Yang L, Peng H, Zhu Z, Li G, Huang Z, Zhao Z . Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. Clin Immunol. 2006; 120(2):171-8. PMC: 7106132. DOI: 10.1016/j.clim.2006.05.002. View

4.
Aichele P, Oehen S, Odermatt B, Zinkernagel R, Hengartner H, Pircher H . Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity. 1997; 6(5):519-29. DOI: 10.1016/s1074-7613(00)80340-4. View

5.
Speiser D, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F . Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005; 115(3):739-46. PMC: 546459. DOI: 10.1172/JCI23373. View